Publications by Laura Jeanbart

Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity

Jeffrey Alan Hubbell, Melody Swartz, Sachiko Hirosue, Laura Jeanbart, Xavier Fredy René Quaglia-Thermes, David Scott Wilson, Giacomo Olimpio Diaceri, Maria Anna Sofia Broggi, Michal Mateusz Raczy, Ruyi Wang

Fully effective vaccines for complex infections must elicit a diverse repertoire of antibodies (humoral immunity) and CD8+ T-cell responses (cellular immunity). Here, we present a synthetic glyco-adjuvant named p(Man-TLR7), which, when conjugated to antige ...

NATURE PUBLISHING GROUP2019

Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma

Melody Swartz, Olivier Michielin, Lambert Charles François Potin, Marcela Rincón-Restrepo, Amanda Waite Lund, Laura Jeanbart, Douglas Hanahan, Sylvie Hauert, Krisztian Homicsko, Natacha Anne-Sophie Bordry, Christopher Claude Giuseppe Tremblay, Manuel Andreas Fankhauser, Maria Anna Sofia Broggi, Elodie Da Costa

In melanoma, vascular endothelial growth factor-C (VEGF-C) expression and consequent lymphangiogenesis correlate with metastasis and poor prognosis. VEGF-C also promotes tumor immunosuppression, suggesting that lymphangiogenesis inhibitors may be clinicall ...

Amer Assoc Advancement Science2017

Engineering opportunities in cancer immunotherapy

Melody Swartz, Laura Jeanbart

Immunotherapy has great potential to treat cancer and prevent future relapse by activating the immune system to recognize and kill cancer cells. A variety of strategies are continuing to evolve in the laboratory and in the clinic, including therapeutic non ...

National Academy of Sciences2015

6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice

Jeffrey Alan Hubbell, Melody Swartz, Iraklis Kourtis, Laura Jeanbart

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that suppress effector T cell responses and can reduce the efficacy of cancer immunotherapies. We previously showed that ultra-small polymer nanoparticles eff ...

Springer2015

Nanoparticle conjugation enhances the immunomodulatory effects of intranasally delivered CpG in house dust mite-allergic mice

Jeffrey Alan Hubbell, Melody Swartz, Alexandre de Titta, Marie Ballester, Laura Jeanbart, Benjamin John Marsland

An emerging strategy in preventing and treating airway allergy consists of modulating the immune response induced against allergens in the lungs. CpG oligodeoxynucleotides have been investigated in airway allergy studies, but even if promising, efficacy re ...

Nature Publishing Group2015

The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine

Mikaël Martino, Jeffrey Alan Hubbell, Alexandre de Titta, Ziad Julier, Laura Jeanbart

Fibronectin (FN) is an extracellular matrix (ECM) protein including numerous fibronectin type III (FNIII) repeats with different functions. The alternatively spliced FN variant containing the extra domain A (FNIII EDA), located between FNIII 11 and FNIII 1 ...

Nature Publishing Group2015

Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes

Jeffrey Alan Hubbell, Melody Swartz, Alexandre de Titta, Marie Ballester, Patricia Corthésy Henrioud, Pedro Romero, Laura Jeanbart

The sentinel or tumor-draining lymph node (tdLN) serves as a metastatic niche for many solid tumors and is altered via tumor-derived factors that support tumor progression and metastasis. tdLNs are often removed surgically, and therapeutic vaccines against ...

Amer Assoc Cancer Research2014

Materials and protein engineering approaches for modulating immunity

Jeffrey Alan Hubbell, Melody Swartz, Alexandre de Titta, Marie Ballester, Stephane Kontos, Kristen Lorentz, Alizée Jéléna Grimm, Laura Jeanbart, David Scott Wilson, Kym Lorenz Brünggel

Amer Chemical Soc2014

Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose

Jeffrey Alan Hubbell, Melody Swartz, Alexandre de Titta, Marie Ballester, Ziad Julier, Laura Jeanbart

In subunit vaccines, strong CD8(+) T-cell responses are desired, yet they are elusive at reasonable adjuvant doses. We show that targeting adjuvant to the lymph node (LN) via ultrasmall polymeric nanoparticles (NPs), which rapidly drain to the LN after int ...

National Academy of Sciences2013

Targeting and Modulating Tumor-Associated Sites with Novel Nanoparticle-Based Immunotherapies

Laura Jeanbart

Cancer is a global disease and a leading cause of death worldwide. While surgery, radiotherapy and chemotherapy comprise the classical tools to eradicate tumors, they do not cure cancer, cannot prevent metastases, lead to side effects, and most importantly ...

EPFL2013